Business
The limited supply of this common reagent is set to drive drug prices higher, but there are ways for companies to lessen the impact.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
A High Court judge in London granted AstraZeneca an injunction, temporarily blocking a former executive from joining rival pharma GSK.
Fiona H. Marshall has been tapped as Novartis Institutes for BioMedical Research president after Jay Bradner’s exit, while Tim Demuth will succeed Malte Peters for MorphoSys.
Mesoblast fell short of analyst forecasts this week, and money is pouring into glaucoma, medical devices for heart disease and chronic endocrine conditions.
Umoja CEO Andy Scharenberg spoke with BioSpace about the company’s unique tri-platform approach to immunotherapy which aims to attack and destroy hematologic and solid organ-based tumors.
Vilya will use its funds for cutting-edge computational techniques to develop innovative drugs for difficult-to-treat diseases.
Despite being the largest minority group in the United States, the contributions of disabled people are remarkedly underreported in the life sciences industry.
The BioForest region is growing up. With a focus on cell and gene therapy, a wealth of talent and proximity to high tech, it is quickly becoming one of biotech’s most exciting hotbeds.
Following the termination of a multi-year collaboration with Takeda, Finch has regained the rights to two assets, FIN-524 and FIN-525, assessed for forms of inflammatory bowel disease.
In an SEC filing, Zymergen revealed it was cutting 80 more jobs and parting with Zach Serber, its co-founder and chief scientific officer.
This week’s Movers & Shakers includes Tessa and Adial bringing in new CEOs, while other companies strengthened their regulatory and medical teams with key appointments